Enzyme:CYP2D6: Difference between revisions
From Pharmacopedia
More actions
| [unchecked revision] | [checked revision] |
MDElliottMD (talk | contribs) Consolidate enzyme entity page to canonical Pharmacopedia: sandbox location per Mark 2026-05-19. Full retrofitted version: history-first spine, collapsible-sortable substrate table, comprehensive-tables pointer, all PMIDs NCBI-eutils-verified, zero em-dashes. For CYP2D6/CYP3A4/CYP2C19 this replaces the earlier pre-retrofit draft with the full version; for the other 8 enzymes this is the first save at the canonical location. Resolves a cross-session sandbox-location duplication: the User:MDEll... |
MDElliottMD (talk | contribs) Add scope="col" to the data-table column headers for screen-reader association (ADA audit M5; designer-claude 2026-05-22) |
||
| (One intermediate revision by the same user not shown) | |||
| Line 8: | Line 8: | ||
{| class="wikitable sortable mw-collapsible mw-collapsed" style="width:100%;" | {| class="wikitable sortable mw-collapsible mw-collapsed" style="width:100%;" | ||
|+ style="white-space:nowrap; text-align:left;" | near-complete CYP2D6 substrate table (click to expand) | |+ style="white-space:nowrap; text-align:left;" | near-complete CYP2D6 substrate table (click to expand) | ||
! Substrate !! Therapeutic class !! CYP2D6 contribution !! Clinical notes | ! scope="col" | Substrate !! scope="col" | Therapeutic class !! scope="col" | CYP2D6 contribution !! scope="col" | Clinical notes | ||
|- | |- | ||
| [[Amitriptyline]] || Tricyclic antidepressant || major || CPIC TCA guideline dose adjustment in CYP2D6 PM/UM. | | [[Amitriptyline]] || Tricyclic antidepressant || major || CPIC TCA guideline dose adjustment in CYP2D6 PM/UM. | ||
| Line 107: | Line 107: | ||
{| class="wikitable" | {| class="wikitable" | ||
! Phenotype !! Abbreviation !! Activity score !! Frequency (varies by ancestry) | ! scope="col" | Phenotype !! scope="col" | Abbreviation !! scope="col" | Activity score !! scope="col" | Frequency (varies by ancestry) | ||
|- | |- | ||
| [[Phenotype:CYP2D6 poor metabolizer|Poor metabolizer]] || PM || 0 || 5–10% (European), 1–2% (East Asian), 3–8% (African) | | [[Phenotype:CYP2D6 poor metabolizer|Poor metabolizer]] || PM || 0 || 5–10% (European), 1–2% (East Asian), 3–8% (African) | ||